ADAR1 Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

ADAR1 Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-24,082	Closed	-$1.13M	–	261
2025 Q2	$1.13M	Sell	24,082 -183,696	-88%	-$8.17M	0.17%	76
2025 Q1	$9.17M	Buy	+207,778	New	+$9.56M	1.7%	12
2024 Q4	–	Sell	-100	Closed	-$3.2K	–	293
2024 Q3	$3.2K	Buy	+100	New	+$3.74K	﹤0.01%	267

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

ADAR1 Capital Management's SWTX Position: Q3 2025 in Review

ADAR1 Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 24,082 shares — an estimated $1.13M sold.

ADAR1 Capital Management first reported a position in SWTX in Q3 2024 and held it in 3 quarters. The position peaked at $9.17M in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

ADAR1 Capital Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
ADAR1 Capital Management sold 24,082 SpringWorks Therapeutics shares in Q3 2025, an estimated $1.13M.
ADAR1 Capital Management first reported a position in SpringWorks Therapeutics in Q3 2024 and held it in 3 quarters.
ADAR1 Capital Management's SpringWorks Therapeutics position peaked at $9.17M in Q1 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.